Erratum to: Triple-negative, basal-like, and quintuple-negative breast cancers: Better prediction model for survival [BMC Cancer. (2011) 10, 507] DOI: 10.1186/1471-2407-10-507;Triple-negative, basal-like, and quintuple-negative breast cancers: Better prediction model for survival

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Choi, Yoon La ^a,b   Oh, Ensel ^c   Park, Sarah ^d   Kim, Yeonju ^e   Park, Yeon Hee ^b   Song, Kyoung ^c   Cho, Eun Y ^b   Hong, Yun Chul ^f   Choi, Jong S ^g   Lee, Jeong E ^b   Kim, Jung H ^b   Nam, Seok J ^b   Im, Young Hyuck ^b   Yang, Jung Hyun ^b   Shin, Young K ^c  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d The Catholic University of Korea   (South Korea)

^e National Cancer Center   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

^g Dongguk University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOKERATIN 5; CYTOKERATIN 6; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; BREAST TUMOR; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; METABOLISM; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; ONCOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MEDICAL ONCOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; TREATMENT OUTCOME;

EID: 77956878979     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-13     Document Type: Erratum

References (28)

1. Sorlie T, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100(14):8418-23. 10.1073/pnas.0932692100, 166244, 12829800.
2. Nielsen TO, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10(16):5367-74. 10.1158/1078-0432.CCR-04-0220, 15328174.
3. Irvin WJ, Carey LA. What is triple-negative breast cancer?. Eur J Cancer 2008, 44(18):2799-2805. 10.1016/j.ejca.2008.09.034, 19008097.
4. Nishimura R, Arima N. Is triple negative a prognostic factor in breast cancer?. Breast Cancer 2008, 15(4):303-8. 10.1007/s12282-008-0042-3, 18369692.
5. Silver DP, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28(7):1145-53. 10.1200/JCO.2009.22.4725, 20100965.
6. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008, 26(15):2568-81. 10.1200/JCO.2007.13.1748, 18487574.
7. Kreike B, et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9(5):R65. 10.1186/bcr1771, 2242660, 17910759.
8. Rakha E, Ellis I, Reis-Filho J. Are triple-negative and basal-like breast cancer synonymous?. Clin Cancer Res 2008, 14(2):618-9. author reply 618, 10.1158/1078-0432.CCR-07-1943, 18223240.
9. Tischkowitz M, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007, 7:134. 10.1186/1471-2407-7-134, 1948892, 17650314.
10. Tan DS, et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. Breast Cancer Res Treat 2008, 111(1):27-44. 10.1007/s10549-007-9756-8, 17922188.
11. Rakha EA, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109(1):25-32. 10.1002/cncr.22381, 17146782.
12. Rakha EA, et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 2009, 15(7):2302-10. 10.1158/1078-0432.CCR-08-2132, 19318481.
13. Cheang MC, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14(5):1368-76. 10.1158/1078-0432.CCR-07-1658, 18316557.
14. Harvey JM, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17(5):1474-81.
15. Kim MJ, et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006, 37(9):1217-26. 10.1016/j.humpath.2006.04.015, 16938528.
16. Yaziji H, et al. HER-2 testing in breast cancer using parallel tissue-based methods. Jama 2004, 291(16):1972-7. 10.1001/jama.291.16.1972, 15113815.
17. Carey LA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295(21):2492-502. 10.1001/jama.295.21.2492, 16757721.
18. van 't Veer LJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415(6871):530-6. 10.1038/415530a, 11823860.
19. van de Vijver MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347(25):1999-2009. 10.1056/NEJMoa021967, 12490681.
20. Wang Y, et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365(9460):671-9.
21. Fadare O, Tavassoli FA. The phenotypic spectrum of basal-like breast cancers: a critical appraisal. Adv Anat Pathol 2007, 14(5):358-73. 10.1097/PAP.0b013e31814b26fe, 17717437.
22. Carey LA, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007, 13(8):2329-34. 10.1158/1078-0432.CCR-06-1109, 17438091.
23. Rouzier R, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005, 11(16):5678-85. 10.1158/1078-0432.CCR-04-2421, 16115903.
24. Conforti R, et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials. Ann Oncol 2007, 18(9):1477-83. 10.1093/annonc/mdm209, 17515403.
25. Ahn SH. Clinical characteristics of breast cancer patients in Korea in 2000. Arch Surg 2004, 139(1):27-30. discussion 31, 10.1001/archsurg.139.1.27, 14718270.
26. Rhee J, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008, 8:307. 10.1186/1471-2407-8-307, 2577689, 18947390.
27. Rosen DG, et al. Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 2004, 17(7):790-7. 10.1038/modpathol.3800120, 15073602.
28. Bertucci F, et al. How basal are triple-negative breast cancers?. Int J Cancer 2008, 123(1):236-40. 10.1002/ijc.23518, 18398844.